title: Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator.
abstract: Fasting mongrel dogs underwent hyperbaric oxygen treatment (HBOT), recombinant tissue plasminogen activator (rt-PA) treatment, and simultaneous HBOT and rt-PA treatment following prior experimental left anterior descending coronary artery occlusion for 2 hours. Thrombosis in and around a copper coil was recorded angiographically at regular intervals, and immediately prior to treatment conclusion. Controls (n = 10) were untreated. Group two animals (n = 10) were treated additionally with 90 minutes of HBOT at 2 atm absolute. Group three animals (n = 8) were treated additionally with 50 mg rt-PA over 90 minutes. Group four animals (n = 10) were treated additionally with simultaneous HBOT and rt-PA over 90 minutes. Myocardial injury was determined by a combination of triphenyltetrazolium chloride histochemical staining and by formazan dye extraction. Damage was measured as a percent of left ventricular cross-sectional area studied. HBOT alone restored 35.9% of oxidative enzyme activity (p greater than 0.001). Treatment with rt-PA alone restored 48.9% of enzyme activity (p greater than 0.001). The combination of HBOT and simultaneous rt-PA resulted in 96.9% restoration of oxidative enzyme activity versus the control group (p greater than 0.001).
authors.affiliation: Department of Surgery and Pathology, Meridia Huron Hospital, Cleveland, OH 44112.
authors.forename: M P
authors.initials: MP
authors.lastname: Thomas
authors.forename: L A
authors.initials: LA
authors.lastname: Brown
authors.forename: D R
authors.initials: DR
authors.lastname: Sponseller
authors.forename: S E
authors.initials: SE
authors.lastname: Williamson
authors.forename: J A
authors.initials: JA
authors.lastname: Diaz
authors.forename: D P
authors.initials: DP
authors.lastname: Guyton
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D004285:Dogs; D005260:Female; D006931:Hyperbaric Oxygenation; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D011994:Recombinant Proteins / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator